SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Apnimed Reports Q3 2026 Net Loss of $29.5 Million, Cash of $351.8 Million

Apnimed reported a third-quarter 2026 net loss of $29.5 million, compared with a $10.9 million loss a year earlier. Revenue was $2.5 million, while cash and cash equivalents totaled $351.8 million at September 30, 2026. The company said its AD109 application remains under FDA review, with a Februar…

APMD

Related stories